Author:
Chimukangara Benjamin,Lessells Richard J.,Singh Lavanya,Grigalionyte Indra,Yende-Zuma Nonhlanhla,Adams Rochelle,Dawood Halima,Dlamini Linda,Buthelezi Sibonisile,Chetty Sheldon,Diallo Karidia,Duffus Wayne A.,Mogashoa Mary,Hagen Melissa B.,Giandhari Jennifer,de Oliveira Tulio,Moodley Pravi,Padayatchi Nesri,Naidoo Kogieleum
Abstract
Abstract
Background
Introduction of tenofovir (TDF) plus lamivudine (3TC) and dolutegravir (DTG) in first- and second-line HIV treatment regimens in South Africa warrants characterization of acquired HIV-1 drug resistance (ADR) mutations that could impact DTG-based antiretroviral therapy (ART). In this study, we sought to determine prevalence of ADR mutations and their potential impact on susceptibility to drugs used in combination with DTG among HIV-positive adults (≥ 18 years) accessing routine care at a selected ART facility in KwaZulu-Natal, South Africa.
Methods
We enrolled adult participants in a cross-sectional study between May and September 2019. Eligible participants had a most recent documented viral load (VL) ≥ 1000 copies/mL after at least 6 months on ART. We genotyped HIV-1 reverse transcriptase and protease genes by Sanger sequencing and assessed ADR. We characterized the effect of ADR mutations on the predicted susceptibility to drugs used in combination with DTG.
Results
From 143 participants enrolled, we obtained sequence data for 115 (80%), and 92.2% (95% CI 85.7–96.4) had ADR. The proportion with ADR was similar for participants on first-line ART (65/70, 92.9%, 95% CI 84.1–97.6) and those on second-line ART (40/44, 90.9%, 95% CI 78.3–97.5), and was present for the single participant on third-line ART. Approximately 89% (62/70) of those on first-line ART had dual class NRTI and NNRTI resistance and only six (13.6%) of those on second-line ART had major PI mutations. Most participants (82%) with first-line viraemia maintained susceptibility to Zidovudine (AZT), and the majority of them had lost susceptibility to TDF (71%) and 3TC (84%). Approximately two in every five TDF-treated individuals had thymidine analogue mutations (TAMs).
Conclusions
Susceptibility to AZT among most participants with first-line viraemia suggests that a new second-line regimen of AZT + 3TC + DTG could be effective. However, atypical occurrence of TAMs in TDF-treated individuals suggests a less effective AZT + 3TC + DTG regimen in a subpopulation of patients. As most patients with first-line viraemia had at least low-level resistance to TDF and 3TC, identifying viraemia before switch to TDF + 3TC + DTG is important to avoid DTG functional monotherapy. These findings highlight a need for close monitoring of outcomes on new standardized treatment regimens.
Funder
centers for disease control and prevention
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Virology,Molecular Medicine
Reference38 articles.
1. UNAIDS. Fast-Track: ending the AIDS epidemic by 2030; 2014. https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. Accessed 25 Mar 2021.
2. World Health Organization. progress report 2016: Prevent HIV, test and treat all: WHO support for country impact; 2016. https://apps.who.int/iris/handle/10665/251713. Accessed 05 Feb 2021.
3. Rhee S-Y, Clutter D, Hare CB, Tchakoute CT, Sainani K, Fessel WJ, et al. Virological failure and acquired genotypic resistance associated with contemporary antiretroviral treatment regimens. Open Forum Infect Dis. 2020;7:ofaa316.
4. WHO. Policy brief: Update of recommendations on first-line antiretroviral regimens, July 2019; 2019. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Accessed 25 Nov 2020.
5. Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, et al. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019;22:e25227–e25227.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献